McKesson Stock Trades at 20% Discount Amid Positive Fair Value Outlook

Key Facts

1McKesson stock is estimated to be 20.7% undervalued, with a fair value of $951.73 based on future cash flows.

2The stock is currently trading at a P/E ratio of 19x, which is below industry averages.

Amid shifting dynamics in the healthcare sector, McKesson (MCK) is emerging as a potential value play following recent price weakness and cooling long-term momentum. According to reports, the stock is estimated to be 20.7% undervalued, with a fair value target of $951.73 based on projected future cash flows. The shares are currently trading at a P/E ratio of 19x, which sits below broader industry averages.

Comparing peers, recent earnings from Cardinal Health (CAH) showed steady growth, while Cencora (COR) maintained robust margins, reinforcing the resilience of the pharmaceutical distribution industry. Per market data, McKesson's 19x P/E ratio positions it attractively against the sector average which often exceeds 22x in certain categories, suggesting continued qualitative growth despite temporary price pressures.

Investors should watch current price levels for MCK, which stood at $612.45 (close May 27, 2026). Regarding the economic calendar, while there are no direct healthcare catalysts in the coming week, global Manufacturing and Services PMI data will be critical to monitor as they dictate broader market sentiment and capital flows into defensive equities.